Interleukin 1 receptor associated kinase 1 (IRAK1) is an emerging therapeutic target in hematologic malignancies, and it has been suggested that IRAKs participate in regulatory interactions with FADD.36 This evidence concerns the gene IRAK1 and hematologic disorder.